Previous 10 | Next 10 |
Verastem recently reported their Q4 and full-year 2021 earnings that revealed substantial headway in their pipeline and on the balance sheet. Verastem secured up to $150M in non-dilutive funding from Oxford Finance. Now, the company expects their cash runway to last through 2025. ...
Why These High-Volume Penny Stocks Are Climbing Right Now Using volume as an indicator for which penny stocks are worth buying can be a great addition to your strategy. While volume is not always the reason a penny stock is gaining, it can be a symptom of a large move. Today, we saw maj...
3 Penny Stocks Under $2 to Watch With Inflation on the Rise Investing in penny stocks can be a high-risk proposition, but it can also pay off handsomely if you find the right company. If you’re willing to do your research and take a gamble, investing in penny stocks under $2 coul...
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain (AIRG) +15%. CoreCivic (CXW) +14%. Renren (RENN) +13%. Losers:...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Verastem press release (NASDAQ:VSTM): Q4 Non-GAAP EPS of -$0.08 beats by $0.04. Revenue of $0.51M (flat Y/Y). Cash, cash equivalents and investments of $100.3M as of December 31, 2021. R&D expenses of $11.4M Shares +9.24% PM. For further details see: Verastem Non-GAAP EPS of -$...
Verastem Oncology (NASDAQ:VSTM) is trading ~9% higher in the pre-market after the development-stage biotech announced its 4Q 2021 results on Monday. In conjunction with the earnings release, Verastem (VSTM) disclosed a non-dilutive financing agreement with Oxford Finance to receive up to $150...
Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evalua...
Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC, Providing Additional Financial Flexibility Expected Cash Runway Through 2025; Supports Continued Development and Potential Commercial Launches of VS-6766 and Defactinib Verastem Oncol...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...